Summarized by Masters of Longevity from Longevity Docs News.
Memory-clinic research on returning blood biomarker results sooner — a trial-based article examining how early disclosure influences diagnostic workflow and clinician decisions.
Key Takeaways
- Returning plasma p-tau217 and NfL results at 3 months produced very high diagnostic confidence in 50% of patients versus 4.6% with 9‑month results.
- Early disclosure altered physicians' management plans and did not increase patient anxiety or depression over the 9‑month period.
- The PLASMAR trial randomized 220 memory clinic patients at a single Spanish center and measured process outcomes rather than clinical benefit.
